Hancock Whitney Corp Has $248,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Hancock Whitney Corp decreased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 11.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,109 shares of the company’s stock after selling 629 shares during the quarter. Hancock Whitney Corp’s holdings in Amphastar Pharmaceuticals were worth $248,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Algert Global LLC bought a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth approximately $3,217,000. Intech Investment Management LLC raised its position in Amphastar Pharmaceuticals by 21.9% in the 3rd quarter. Intech Investment Management LLC now owns 12,989 shares of the company’s stock valued at $630,000 after purchasing an additional 2,331 shares during the last quarter. Aurora Investment Counsel grew its holdings in shares of Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock worth $2,654,000 after purchasing an additional 232 shares during the last quarter. Segall Bryant & Hamill LLC bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $921,000. Finally, Quest Partners LLC increased its stake in shares of Amphastar Pharmaceuticals by 74.4% in the third quarter. Quest Partners LLC now owns 7,586 shares of the company’s stock valued at $368,000 after buying an additional 3,237 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO William J. Peters sold 7,426 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the sale, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. This represents a 7.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,533 shares of company stock valued at $1,378,252 in the last 90 days. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Stock Up 2.2 %

NASDAQ:AMPH opened at $45.21 on Thursday. The firm has a market capitalization of $2.17 billion, a P/E ratio of 14.74, a P/E/G ratio of 0.89 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The stock’s fifty day simple moving average is $48.10 and its 200-day simple moving average is $44.50. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company started coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $60.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.